Charise Gleason, MSN, NP-BC, AOCNP

Advanced Practice Provider Chief, Winship Cancer Institute,
Emory University,
Atlanta, GA

Ms Gleason is Advanced Practice Provider Chief, Winship Cancer Institute, Emory University, Atlanta, GA, where she oversees the clinical practice, quality, safety, education, and the Advanced Practice Provider Fellowship Program. Ms Gleason obtained her bachelor’s degree in nursing and master’s degree in nursing with a subspecialty in oncology from Emory University. Her clinical practice focuses around multiple myeloma, including retreatment settings, multidisciplinary care, novel therapies, and patient support. In addition, Ms Gleason is responsible for development and oversight of oncology advanced practice guidelines.

Authored Items

Patient Support Services in Multiple Myeloma

Charise Gleason, MSN, NP-BC, AOCNP, Chelsea Sprouse, RN-BSN, MSN, NP-C, Kathryn Maples, PharmD, BCOP

Interview with the Innovators

Video Library

Charise Gleason, MSN, NP-C, AOCNP, Kathryn Maples, PharmD, BCOP, and Chelsea Sprouse, FNP-C, discuss their personal experiences with patient support groups for multiple myeloma patients that deal with pharmacy issues, financial problems, management of pain and neuropathy, psychological and nutritional support.

Oral Therapies for Multiple Myeloma

Charise Gleason, MSN, NP-BC, AOCNP, Chelsea Sprouse, RN-BSN, MSN, NP-C, Kathryn Maples, PharmD, BCOP

Interview with the Innovators

Video Library

Charise Gleason, MSN, NP-C, AOCNP, Kathryn Maples, PharmD, BCOP, and Chelsea Sprouse, FNP-C, share their experiences with complex treatment regimens that include oral therapy, especially as it relates to patients’ appropriate adherence to therapy.

Moving Multiple Myeloma Treatment from IV Infusions to SQ Injections

Charise Gleason, MSN, NP-BC, AOCNP, Chelsea Sprouse, RN-BSN, MSN, NP-C, Kathryn Maples, PharmD, BCOP

Interview with the Innovators

Video Library

Charise Gleason, MSN, NP-C, AOCNP, Kathryn Maples, PharmD, BCOP, and Chelsea Sprouse, FNP-C, discuss their perspectives on using SQ treatments for MM, including the benefits for the patients, along with a requirement for education and training for nurses with respect to delivering a high volume injection into the SQ space.

Dealing with Multidrug Combination Therapy for Multiple Myeloma

Charise Gleason, MSN, NP-BC, AOCNP, Chelsea Sprouse, RN-BSN, MSN, NP-C, Kathryn Maples, PharmD, BCOP

Interview with the Innovators

Video Library

Charise Gleason, MSN, NP-C, AOCNP, Kathryn Maples, PharmD, BCOP, and Chelsea Sprouse, FNP-C, describe their approach to advising patients on combination therapy, especially with multidrug regimens, and counseling them on treatments that may be needed to prevent or treat therapy-related adverse events.

Best Practices in Counseling Multiple Myeloma Patients on Therapeutic Options

Charise Gleason, MSN, NP-BC, AOCNP, Chelsea Sprouse, RN-BSN, MSN, NP-C, Kathryn Maples, PharmD, BCOP

Interview with the Innovators

Video Library

Charise Gleason, MSN, NP-C, AOCNP, Kathryn Maples, PharmD, BCOP, and Chelsea Sprouse, FNP-C, provide their perspectives on how to counsel patients on the best frontline treatment options for newly-diagnosed MM, and how this differs from relapsed/refractory MM, where individualizing treatment plans based on the patient needs and tolerability of treatment is key.

Landscape Shifts in Treating Multiple Myeloma

Charise Gleason, MSN, NP-BC, AOCNP, Kathryn Maples, PharmD, BCOP, Chelsea Sprouse, RN-BSN, MSN, NP-C

Interview with the Innovators

Video Library

Charise Gleason, MSN, NP-C, AOCNP, Kathryn Maples, PharmD, BCOP, and Chelsea Sprouse, FNP-C, enumerate the major landscape shifts over the past 5 years in treating MM, including an increasing number of treatment options, the emergence of MRD testing to guide therapy, the availability of clinical trials, and the deeper, more durable responses new agents provide.

Benefits and Challenges with Emerging Agents for Multiple Myeloma

Charise Gleason, MSN, NP-BC, AOCNP, Kathryn Maples, PharmD, BCOP, Chelsea Sprouse, RN-BSN, MSN, NP-C

Interview with the Innovators

Video Library

Charise Gleason, MSN, NP-C, AOCNP, Kathryn Maples, PharmD, BCOP, and Chelsea Sprouse, FNP-C, discuss the convenience of oral therapy along with challenges in adherence to oral therapy. Additionally, they’ll discuss the tolerability of emerging drugs, the emergence of novel adverse events with new agents, and best practices in providing supportive care for patients on these novel agents.

Emerging Treatments in Multiple Myeloma

Kathryn Maples, PharmD, BCOP, Charise Gleason, MSN, NP-BC, AOCNP

Interview with the Innovators

Video Library

Charise Gleason, MSN, NP-C, AOCNP, Kathryn Maples, PharmD, BCOP, and Chelsea Sprouse, FNP-C, talk about the emerging treatments for MM, including monoclonal antibodies, 2nd-generation protease inhibitors, and targeted therapies. These changes pose challenges to healthcare providers struggling to keep up with these changes, but this is good news for patients with expanding treatment options.

Current Standard of Care for Patients with Multiple Myeloma Based on Their Eligibility for Autologous Stem-Cell Transplant

Charise Gleason, MSN, NP-BC, AOCNP, Kathryn Maples, PharmD, BCOP, Chelsea Sprouse, RN-BSN, MSN, NP-C

Interview with the Innovators

Video Library

Charise Gleason, MSN, NP-BC, AOCNP, Kathryn Maples, PharmD, BCOP, and Chelsea Sprouse, RN-BSN, MSN, NP-C, discuss the current standard of care for both high- and low-risk patients with newly diagnosed or recurrent/refractory multiple myeloma who are initially not eligible for autologous stem-cell transplant and who subsequently become transplant-eligible.

Standard of Care Therapy for Transplant Eligible Patients with Multiple Myeloma Based on Risk Stratification

Charise Gleason, MSN, NP-BC, AOCNP, Kathryn Maples, PharmD, BCOP, Chelsea Sprouse, RN-BSN, MSN, NP-C

Interview with the Innovators

Video Library

Charise Gleason, MSN, NP-C, AOCNP, Kathryn Maples, PharmD, BCOP, and Chelsea Sprouse, FNP-C discuss their approach to the care of transplant-eligible patients with multiple myeloma, particularly based on the patients' risk stratification, as well as poor-prognosis cytogenetics including those with (4,14) translocation.

Charise Gleason, MSN, NP-BC, AOCNP

Authored Items

Connect with Us

Subscribe Today!

I'd like to receive:

Please enter your mailing address.

We Value Your Feedback! Tell Us How You Consume Content